Abemaciclib - Latest Advances

Emerging Targeted Therapies and Ongoing Clinical Trials in Pediatric Brain Tumors

Journal: No shinkei geka. Neurological surgery

Published: December 09, 2025

Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.

Journal: Journal of medical economics

Published: December 05, 2025

Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Global Challenges and Tibremciclib Perspective.

Journal: JCO global oncology

Published: December 04, 2025

Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax.

Journal: Research square

Published: December 03, 2025

Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis.

Journal: Journal of managed care & specialty pharmacy

Published: November 26, 2025

Risk Factors for Dose Reduction in Patients Receiving Abemaciclib-A Multicenter Retrospective Study

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: November 18, 2025

Correction: Abemaciclib early access - an Italian experience.

Journal: Frontiers in oncology

Published: October 28, 2025

Accuracy of Budget Impact Projections in Bulgarian Health Technology Assessment: A Five-Year Validation Study (2020-2025).

Journal: Healthcare (Basel, Switzerland)

Published: October 28, 2025

Oral Tamoxifen and Abemaciclib in Postoperative Therapy for Male Breast Cancer: A Case Report.

Journal: The American journal of case reports

Published: October 26, 2025

Molecular interaction of abemaciclib with human serum albumin: Insights from spectroscopy, microscopy, and computational approaches.

Journal: International journal of biological macromolecules

Published: October 22, 2025

Renal adverse events associated with cyclin-dependent kinase 4/6 inhibitors.

Journal: Cancer treatment reviews

Published: October 16, 2025

Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 15, 2025

Filters

Emerging Targeted Therapies and Ongoing Clinical Trials in Pediatric Brain Tumors

Emerging Targeted Therapies and Ongoing Clinical Trials in Pediatric Brain Tumors

Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.

Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.

Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Global Challenges and Tibremciclib Perspective.

Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Global Challenges and Tibremciclib Perspective.

Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax.

Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax.

Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis.

Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis.

Risk Factors for Dose Reduction in Patients Receiving Abemaciclib-A Multicenter Retrospective Study

Risk Factors for Dose Reduction in Patients Receiving Abemaciclib-A Multicenter Retrospective Study

Correction: Abemaciclib early access - an Italian experience.

Correction: Abemaciclib early access - an Italian experience.

Accuracy of Budget Impact Projections in Bulgarian Health Technology Assessment: A Five-Year Validation Study (2020-2025).

Accuracy of Budget Impact Projections in Bulgarian Health Technology Assessment: A Five-Year Validation Study (2020-2025).

Oral Tamoxifen and Abemaciclib in Postoperative Therapy for Male Breast Cancer: A Case Report.

Oral Tamoxifen and Abemaciclib in Postoperative Therapy for Male Breast Cancer: A Case Report.

Molecular interaction of abemaciclib with human serum albumin: Insights from spectroscopy, microscopy, and computational approaches.

Molecular interaction of abemaciclib with human serum albumin: Insights from spectroscopy, microscopy, and computational approaches.

Renal adverse events associated with cyclin-dependent kinase 4/6 inhibitors.

Renal adverse events associated with cyclin-dependent kinase 4/6 inhibitors.

Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].

Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].